RAV12 in Treating Patients With Metastatic or Recurrent Adenocarcinoma

PHASE1CompletedINTERVENTIONAL
Enrollment

53

Participants

Timeline

Start Date

December 31, 2004

Primary Completion Date

May 31, 2008

Study Completion Date

May 31, 2008

Conditions
Cancer
Interventions
BIOLOGICAL

monoclonal antibody RAV12

Escalating doses of RAV12 (weekly 0.3, 1.0, 1.5, 3.0, 4.0, 5.0, 6.0 mg/kg or 0.5 mg/kg BIW or TIW; 0.75 mg/kg BIW) for 4 weeks

Trial Locations (5)

20007

Lombardi Comprehensive Cancer Center at Georgetown University Medical Center, Washington D.C.

33136

University of Miami Sylvester Comprehensive Cancer Center - Miami, Miami

37203

Sarah Cannon Cancer Center at Centennial Medical Center, Nashville

90404

Premiere Oncology, Santa Monica

19111-2497

Fox Chase Cancer Center - Philadelphia, Philadelphia

Sponsors

Lead Sponsor

All Listed Sponsors
lead

MacroGenics

INDUSTRY